Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers

Conditions:   Colorectal Carcinoma;   Gastric Adenocarcinoma;   Esophageal and GEJ Adenocarcinoma;   Cholangiocarcinoma;   Gallbladder Carcinoma Interventions:   Drug: tucatinib;   Drug: trastuzumab;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: fluorouracil Sponsor:   Seattle Genetics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials